Eli Lilly and Company announced a definitive agreement on November 16, 2026, to acquire Calytrix Bio. The deal, valued at up to $1.5 billion in cash, includes an upfront payment and additional funds tied to clinical and regulatory milestones. This acquisition adds a preclinical biparatopic antibody targeting mutant calreticulin-driven essential thrombocythemia and myelofibrosis to Lilly's oncology pipeline.
Lilly agreed to acquire Calytrix Bio, with shareholders receiving up to $1.5 billion in cash including upfront and milestone payments. The deal broadens Lilly's myeloproliferative neoplasm pipeline with a preclinical antibody for mCALR-driven essential thrombocythemia and myelofibrosis. For a company of Lilly's size this outlay is small and the asset is still preclinical, so no material price effect is expected in the near term.
- • Definitive agreement announced November 16, 2026 for Lilly to acquire Calytrix Bio
- • Up to $1.5 billion in cash including upfront and milestone payments
- • Lead asset is preclinical with clinical and regulatory milestones still to be met
- • Payments contingent on achievement of clinical and regulatory milestones